What is Theravance Biopharma, Inc.'s earnings per share (EPS)?

Theravance Biopharma, Inc. (TBPH) reported diluted earnings per share of $2.06 for fiscal year 2025. This represents a 279.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Theravance Biopharma, Inc. (TBPH) Financials

TBPH

FY2025 annual

Revenue $107.5M +66.9% YoY

Net Income $105.9M +287.7% YoY

EPS (Diluted) $2.06 +279.1% YoY

Free Cash Flow $238.5M +2109.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TBPH SEC filings page.

Theravance Biopharma, Inc. (TBPH) reported $107.5M in revenue for fiscal year 2025, up 66.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TBPH FY2025 2026-10-03

Revenue expansion nearly closed the operating deficit, but 2025’s earnings and cash inflow came from different economic engines.

In FY2025, operating cash flow reached $238M while operating income remained a loss of $3.6M; cash generation therefore cannot be read as recurring operating profitability. Free cash flow nearly matched operating cash flow, with only $42K of capital expenditure, indicating that the year’s cash result required almost no reinvestment and was driven primarily by operating cash items.

The business showed operating leverage: revenue rose 67.0% in FY2025 while selling, general and administrative costs plus R&D increased only modestly, allowing the operating loss to narrow to $3.6M. That reflects scale absorbing a largely fixed cost base, not yet consistent operating profitability.

Short-term balance-sheet liquidity strengthened materially, with the current ratio rising from 5.0x in FY2024 to 10.9x in FY2025. Total liabilities were $189M, while net income far exceeded operating income, so reported profit does not describe the core cost-and-revenue engine.

Financial Health Signals

Financial Health Score 77/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Theravance Biopharma, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Theravance Biopharma, Inc. held $326.5M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $238.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Theravance Biopharma, Inc. scores 86/100 among other emerging companies.

Dilution

Theravance Biopharma, Inc. had 51M shares outstanding at the end of fiscal year 2025, against 49M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Theravance Biopharma, Inc. scores 61/100 among other emerging companies.

R&D Intensity

Theravance Biopharma, Inc. spent $37.4M on research and development in fiscal year 2025, which was 33.7% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Theravance Biopharma, Inc. scores 66/100 among other emerging companies.

Revenue Progress

Theravance Biopharma, Inc. reported revenue of $107.5M in fiscal year 2025, against $64.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Theravance Biopharma, Inc. scores 75/100 among other emerging companies.

Burn Trend

100

Theravance Biopharma, Inc.'s operations generated $238.5M of cash in fiscal year 2025, against $11.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Theravance Biopharma, Inc. scores 100/100 among other emerging companies.

Balance Sheet

Theravance Biopharma, Inc.'s cash, cash equivalents and investments came to $326.5M at the end of fiscal year 2025, against $188.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Theravance Biopharma, Inc. scores 71/100 among other emerging companies.

Altman Z-Score Distress

1.47

Theravance Biopharma, Inc. scores 1.47, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($884.2M) relative to total liabilities ($188.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/7

Theravance Biopharma, Inc. passes 6 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.25x

For every $1 of reported earnings, Theravance Biopharma, Inc. generates $2.25 in operating cash flow ($238.5M OCF vs $105.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

N/A

Theravance Biopharma, Inc. reported an operating loss of $3.6M against $2.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$20.7M

YoY-20.9%

QoQ+17.1%

5Y CAGR+9.9%

10Y CAGR+14.2%

Theravance Biopharma, Inc. generated $20.7M in revenue in Q2 2026. This represents a decrease of 20.9% from the same quarter a year earlier. Against the prior quarter it is up 17.1%.

Net Income

-$5.9M

YoY-110.8%

QoQ-19.6%

Theravance Biopharma, Inc. reported -$5.9M in net income in Q2 2026. This represents a decrease of 110.8% from the same quarter a year earlier. Against the prior quarter it is down 19.6%.

EPS (Diluted)

-$0.11

YoY-110.2%

QoQ-10.0%

Theravance Biopharma, Inc. earned -$0.11 per diluted share (EPS) in Q2 2026. This represents a decrease of 110.2% from the same quarter a year earlier. Against the prior quarter it is down 10.0%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$219.8M

YoY-22.0%

QoQ-23.7%

5Y CAGR+1.4%

10Y CAGR+4.0%

Theravance Biopharma, Inc. held $219.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

52M

YoY+3.1%

QoQ+0.7%

5Y CAGR-6.7%

10Y CAGR+0.8%

Theravance Biopharma, Inc. had 52M shares outstanding in Q2 2026. This represents an increase of 3.1% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

-39.9%

YoY-29.5pp

QoQ+13.7pp

Theravance Biopharma, Inc.'s operating margin was -39.9% in Q2 2026, reflecting core business profitability. This is down 29.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.7 percentage points.

Net Margin

-28.4%

QoQ-0.6pp

Theravance Biopharma, Inc.'s net profit margin was -28.4% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is down 0.6 percentage points. No change is given against Q2 2025: its reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

-2.0%

YoY-26.4pp

QoQ-0.3pp

Theravance Biopharma, Inc.'s ROE was -2.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 26.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$4.7M

YoY-55.1%

QoQ-19.2%

Theravance Biopharma, Inc. invested $4.7M in research and development in Q2 2026. This represents a decrease of 55.1% from the same quarter a year earlier. Against the prior quarter it is down 19.2%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

TBPH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TBPH quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$104.3M	$107.5M+66.9%	$64.4M+12.1%	$57.4M+11.8%	$51.3M-7.2%	$55.3M-23.0%	$71.9M-2.1%	$73.4M+21.6%	$60.4M+292.4%	$15.4M-68.4%	$48.6M+15.5%	$42.1M+260.4%	$11.7M+5071.7%	$226K-99.8%	$130.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$6.0M+108.4%	$2.9M-37.9%	$4.7M+14.8%	$4.1M	$0	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$9.4M-79.6%	$45.8M+22.1%	$37.5M+391.1%	$7.6M+3276.1%	$226K-99.8%	$130.1M
R&D Expenses	N/A	$37.4M-0.6%	$37.6M-7.3%	$40.6M-35.9%	$63.4M-67.3%	$193.7M-25.8%	$261.0M+19.0%	$219.2M+8.9%	$201.3M+15.8%	$173.9M+22.7%	$141.7M+9.7%	$129.2M-23.4%	$168.5M+39.8%	$120.6M+5.8%	$114.0M
SG&A Expenses	N/A	$73.7M+6.5%	$69.2M-1.3%	$70.1M+4.5%	$67.1M-32.5%	$99.3M-8.5%	$108.5M+2.3%	$106.1M+9.3%	$97.1M+1.5%	$95.6M+13.1%	$84.5M-6.3%	$90.2M+25.9%	$71.6M+99.4%	$35.9M+39.7%	$25.7M
Operating Income	-$4.2M	-$3.6M+92.3%	-$46.9M+16.2%	-$56.0M+39.1%	-$92.0M+64.3%	-$257.8M+13.4%	-$297.6M-18.1%	-$251.9M-5.5%	-$238.8M+8.2%	-$260.1M-44.1%	-$180.5M+0.8%	-$181.9M+21.8%	-$232.5M	N/A	-$9.6M
EBITDA	N/A	-$2.1M+95.4%	-$45.3M+16.2%	-$54.1M+39.4%	-$89.4M+64.3%	-$250.5M+13.9%	-$291.0M-18.6%	-$245.4M-4.2%	-$235.6M+8.0%	-$256.1M-44.4%	-$177.3M+0.9%	-$178.9M+22.0%	-$229.3M	N/A	-$6.3M
Interest Expense	N/A	$2.5M-3.3%	$2.5M+8.3%	$2.4M-63.1%	$6.4M-25.5%	$8.5M0.0%	$8.5M-73.2%	$31.9M+204.0%	$10.5M+22.6%	$8.5M+508.8%	$1.4M	$0	$0	N/A	N/A
Income Tax	N/A	$23.4M+97.8%	$11.8M+99.3%	$5.9M+65722.2%	$9K+106.0%	-$151K+98.2%	-$8.5M-63.2%	-$5.2M+50.6%	-$10.6M-177.1%	$13.7M+35.5%	$10.1M+963.1%	$951K-85.1%	$6.4M	$0	$0
Net Income	$53.8M	$105.9M+287.7%	-$56.4M-2.2%	-$55.2M-106.3%	$872.1M+537.3%	-$199.4M+28.3%	-$278.0M-17.6%	-$236.5M-9.7%	-$215.5M+24.5%	-$285.4M-49.7%	-$190.7M-4.6%	-$182.2M+23.1%	-$237.0M	N/A	-$9.6M
EPS (Basic)	N/A	$2.10+282.6%	-$1.15-15.0%	-$1.00-108.4%	$11.85+512.9%	-$2.87+35.7%	-$4.46-4.9%	-$4.25	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$1.01	$2.06+279.1%	-$1.15-15.0%	-$1.00-108.4%	$11.85+512.9%	-$2.87+35.7%	-$4.46-4.9%	-$4.25	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	52M+5.4%	49M-11.7%	55M-24.9%	74M+5.9%	69M+11.4%	62M+12.1%	56M+3.0%	54M+3.1%	52M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Revenue	$20.7M-20.9%	$17.7M+15.0%	$45.9M+144.7%	$20.0M+18.5%	$26.2M+83.7%	$15.4M+6.1%	$18.8M+6.8%	$16.9M+7.5%
R&D Expenses	$4.7M-55.1%	$5.8M-49.1%	N/A	$8.1M-12.5%	$10.5M+5.4%	$11.5M+27.7%	N/A	$9.3M+11.5%
SG&A Expenses	$14.2M-23.1%	$17.7M-3.5%	N/A	$18.3M+8.6%	$18.4M+8.1%	$18.4M+9.7%	N/A	$16.9M+4.5%
Operating Income	-$8.3M-203.7%	-$9.5M+34.3%	$20.0M+317.5%	-$6.5M+40.4%	-$2.7M+82.6%	-$14.4M-28.8%	-$9.2M-47.4%	-$10.8M-23.7%
Interest Expense	N/A	N/A	N/A	$573K-9.0%	$663K+3.0%	$643K+2.2%	N/A	$630K+3.4%
Income Tax	$1.1M-94.0%	-$1.5M-175.0%	N/A	-$6.5M-345.8%	$18.4M+1304.5%	-$559K-144.3%	N/A	$2.6M+93.6%
Net Income	-$5.9M-110.8%	-$4.9M+63.7%	$61.0M+493.0%	$3.6M+128.5%	$54.8M+431.8%	-$13.6M-16.4%	-$15.5M-82.5%	-$12.7M-41.9%
EPS (Basic)	-$0.11-110.1%	-$0.10+63.0%	$1.20+487.1%	$0.07+126.9%	$1.09+420.6%	-$0.27-12.5%	-$0.31-82.4%	-$0.26-52.9%
EPS (Diluted)	-$0.11-110.2%	-$0.10+63.0%	$1.15+471.0%	$0.07+126.9%	$1.08+417.6%	-$0.27-12.5%	-$0.31-82.4%	-$0.26-52.9%
Diluted Shares (Avg)	52M+1.9%	51M+3.2%	N/A	52M+5.9%	51M+4.1%	50M+2.9%	N/A	49M-6.3%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA.

TBPH Balance Sheet

TBPH quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$485.6M+37.1%	$354.2M-7.3%	$382.0M-37.1%	$607.4M+62.1%	$374.8M-20.1%	$469.1M+14.7%	$408.8M-27.0%	$560.2M+26.9%	$441.4M-31.0%	$639.3M+113.0%	$300.1M-11.1%	$337.8M+1241.6%	$25.2M	N/A
Current Assets	$418.5M+159.8%	$161.1M+20.6%	$133.5M-62.2%	$353.5M+41.5%	$249.9M-36.5%	$393.3M+16.2%	$338.5M-36.5%	$532.8M+40.7%	$378.7M-28.3%	$528.5M+122.6%	$237.5M-13.8%	$275.4M+1852.1%	$14.1M	N/A
Cash & Equivalents	$167.8M+344.0%	$37.8M-4.4%	$39.5M-86.7%	$298.2M+231.5%	$90.0M+10.4%	$81.5M+40.3%	$58.1M-84.6%	$378.0M+324.8%	$89.0M-74.2%	$344.7M+205.8%	$112.7M+26.3%	$89.2M	$0	$0
Short-Term Investments	$147.6M+191.9%	$50.6M-19.6%	$62.9M+114.5%	$29.3M-64.9%	$83.5M-60.5%	$211.5M-5.1%	$222.8M+75.1%	$127.3M-51.0%	$259.6M+66.0%	$156.4M+161.8%	$59.7M-63.9%	$165.4M	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$16.8M+37.7%	$12.2M+22.1%	$10.0M-20.3%	$12.5M+20.6%	$10.4M	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$620K-72.5%	$2.3M+248.8%	$646K-66.4%	$1.9M+565.1%	$289K+45.2%	$199K	N/A
Long-Term Investments	$11.1M	$0	$0	$0	$0	$0-100.0%	$5.0M-58.0%	$11.9M-71.5%	$41.6M-54.6%	$91.6M+113.6%	$42.9M-16.6%	$51.4M	$0	$0
Total Liabilities	$188.8M+5.7%	$178.6M+5.7%	$169.0M+2.1%	$165.6M-76.8%	$713.4M-7.7%	$772.8M+22.2%	$632.7M+3.4%	$611.8M+87.5%	$326.2M+12.9%	$289.0M+406.6%	$57.1M+18.9%	$48.0M+13.7%	$42.2M	N/A
Current Liabilities	$38.3M+19.4%	$32.1M+29.5%	$24.8M-13.7%	$28.7M-51.0%	$58.6M-52.6%	$123.6M+10.6%	$111.7M+13.3%	$98.6M+57.6%	$62.6M+27.0%	$49.3M-0.4%	$49.5M+19.9%	$41.3M+11.9%	$36.9M	N/A
Non-Current Liabilities	$150.5M+2.7%	$146.5M+1.6%	$144.2M+5.4%	$136.9M-79.1%	$654.8M+0.9%	$649.2M+24.6%	$521.0M+1.5%	$513.3M+94.7%	$263.7M+10.0%	$239.8M+3062.6%	$7.6M+12.7%	$6.7M+25.5%	$5.4M	N/A
Long-Term Debt	N/A	N/A	$0	N/A	$616.3M-0.5%	$619.2M+36.1%	$455.0M+0.2%	$454.4M+103.1%	$223.7M	N/A	N/A	N/A	N/A	N/A
Total Equity	$296.7M+69.0%	$175.5M-17.6%	$213.0M-51.8%	$441.8M+230.5%	-$338.6M-11.5%	-$303.8M-35.7%	-$223.8M-333.9%	-$51.6M-144.8%	$115.2M-67.1%	$350.2M+44.1%	$243.1M-16.1%	$289.8M+1801.1%	-$17.0M-143.7%	-$7.0M
Retained Earnings	-$859.6M+11.0%	-$965.5M-6.2%	-$909.1M-6.5%	-$853.9M+50.5%	-$1.7B-13.1%	-$1.5B-22.3%	-$1.2B-23.4%	-$1.0B-26.9%	-$797.7M-55.7%	-$512.2M-59.3%	-$321.6M-130.8%	-$139.3M	$0	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Total Assets	$469.8M+10.3%	$472.3M+37.5%	$485.6M+37.1%	$415.5M+16.7%	$426.0M+17.7%	$343.6M-7.5%	$354.2M-7.3%	$356.1M-13.9%
Current Assets	$416.7M+13.8%	$417.6M+177.9%	$418.5M+159.8%	$354.7M+204.5%	$366.3M+207.0%	$150.3M+20.9%	$161.1M+20.6%	$116.5M-28.0%
Cash & Equivalents	$219.8M-22.0%	$288.1M+160.5%	$167.8M+344.0%	$174.8M+647.6%	$281.9M+508.3%	$110.6M+105.5%	$37.8M-4.4%	$23.4M-67.4%
Short-Term Investments	$167.9M+195.2%	$106.6M+426.5%	$147.6M+191.9%	$154.9M+127.9%	$56.9M+14.4%	$20.2M-56.1%	$50.6M-19.6%	$68.0M+9.1%
Long-Term Investments	$0	$0	$11.1M	$3.0M	$0	$0	$0	$0
Total Liabilities	$180.1M-10.5%	$181.7M+2.3%	$188.8M+5.7%	$182.8M+7.2%	$201.2M+19.5%	$177.6M+6.7%	$178.6M+5.7%	$170.5M+1.8%
Current Liabilities	$30.8M-43.7%	$31.8M+0.9%	$38.3M+19.4%	$37.4M+59.6%	$54.6M+138.1%	$31.5M+45.4%	$32.1M+29.5%	$23.4M-7.6%
Non-Current Liabilities	$149.3M+1.9%	$149.9M+2.6%	$150.5M+2.7%	$145.4M-1.1%	$146.6M+0.8%	$146.1M+0.9%	$146.5M+1.6%	$147.0M+3.5%
Total Equity	$289.7M+28.8%	$290.6M+75.1%	$296.7M+69.0%	$232.7M+25.3%	$224.8M+16.1%	$166.0M-19.0%	$175.5M-17.6%	$185.7M-24.6%
Retained Earnings	-$870.5M+5.8%	-$864.6M+11.7%	-$859.6M+11.0%	-$920.7M+3.1%	-$924.3M+1.4%	-$979.1M-6.3%	-$965.5M-6.2%	-$950.0M-5.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

TBPH Cash Flow Statement

TBPH quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$53.7M	$238.5M+2168.0%	-$11.5M+57.3%	-$27.0M+85.6%	-$187.0M+10.0%	-$207.9M+17.0%	-$250.4M-5.1%	-$238.2M-111.0%	-$112.9M+43.9%	-$201.1M-103.1%	-$99.0M+41.4%	-$168.9M+3.6%	-$175.2M-44.8%	-$121.0M-1.6%	-$119.1M
Depreciation & Amortization	N/A	$1.5M-6.3%	$1.6M-15.8%	$1.9M-26.9%	$2.6M-64.3%	$7.3M+9.7%	$6.6M+1.8%	$6.5M+106.1%	$3.2M-21.4%	$4.0M+29.1%	$3.1M+4.3%	$3.0M-8.7%	$3.3M+23.4%	$2.7M-18.4%	$3.3M
Stock-Based Compensation	N/A	$18.5M-13.6%	$21.4M-15.7%	$25.4M-36.1%	$39.7M-36.0%	$62.1M-1.5%	$63.0M+4.2%	$60.5M+17.8%	$51.3M+4.4%	$49.1M+19.4%	$41.2M-23.8%	$54.0M+25.0%	$43.2M+92.4%	$22.5M+5.4%	$21.3M
Capital Expenditures	N/A	$42K-87.3%	$332K-86.7%	$2.5M+335.0%	$572K-83.2%	$3.4M-48.5%	$6.6M+108.3%	$3.2M-56.1%	$7.2M+200.9%	$2.4M+12.7%	$2.1M-19.3%	$2.6M-14.8%	$3.1M+13.6%	$2.7M+5.6%	$2.6M
Free Cash Flow	N/A	$238.5M+2109.8%	-$11.9M+59.8%	-$29.5M+84.3%	-$187.6M+11.2%	-$211.3M+17.8%	-$257.0M-6.5%	-$241.4M-101.0%	-$120.1M+41.0%	-$203.5M-101.2%	-$101.1M+41.0%	-$171.5M+3.8%	-$178.3M-44.1%	-$123.7M-1.6%	-$121.7M
Investing Cash Flow	-$107.5M	-$105.3M-957.1%	$12.3M+137.6%	-$32.7M-102.8%	$1.2B+827.0%	$124.5M+1061.2%	$10.7M+112.9%	-$83.1M-147.0%	$176.7M+413.7%	-$56.3M+62.0%	-$148.2M-233.5%	$111.0M	N/A	N/A	N/A
Financing Cash Flow	-$8.4M	-$3.2M-30.1%	-$2.5M+98.7%	-$198.9M+73.8%	-$758.8M-926.0%	$91.9M-65.1%	$263.1M+20278.4%	$1.3M-99.4%	$225.2M+13499.0%	$1.7M-99.7%	$479.2M+489.4%	$81.3M	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$445K-99.8%	$197.1M+53.0%	$128.8M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Operating Cash Flow	-$7.0M-103.3%	$73.3M+70.3%	-$6.1M-572.3%	-$6.5M-25.3%	$208.1M+4812.9%	$43.0M+4311.3%	-$902K-5.6%	-$5.2M-109.0%
Stock-Based Compensation	$6.0M+31.9%	$4.5M-7.6%	N/A	$4.6M-7.8%	$4.5M-15.5%	$4.9M-6.7%	N/A	$5.0M-20.7%
Capital Expenditures	N/A	N/A	$8K-95.8%	$0-100.0%	N/A	N/A	$190K-71.9%	$15K-28.6%
Free Cash Flow	N/A	N/A	-$6.1M-456.0%	-$6.5M-24.9%	N/A	N/A	-$1.1M+28.7%	-$5.2M-107.9%
Investing Cash Flow	-$60.4M-66.6%	$52.6M+71.7%	$588K-96.3%	-$100.2M-476.2%	-$36.3M-1096.2%	$30.6M+79.9%	$15.7M+2417.0%	-$17.4M-82752.4%
Financing Cash Flow	-$967K-92.2%	-$5.6M-553.0%	-$1.5M-308.5%	-$400K-7.5%	-$503K-1043.2%	-$854K+50.2%	-$365K+98.8%	-$372K+98.8%
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$0-100.0%

Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid.

TBPH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TBPH quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	60.8%-33.2pp	94.0%+5.1pp	88.9%+23.7pp	65.3%-34.7pp	100.0%0.0pp	100.0%
Operating Margin	-3.4%+69.6pp	-72.9%+24.7pp	-97.6%	-179.1%	-466.1%	-414.2%	-343.1%	-395.5%	-1690.7%	-371.0%	-431.8%	-1989.5%	N/A	-7.4%
Net Margin	98.5%+186.2pp	-87.6%+8.5pp	-96.1%	1698.5%	-360.6%	-386.9%	-322.1%	-357.0%	-1855.0%	-391.9%	-432.6%	-2028.0%	N/A	-7.4%
Return on Equity	35.7%+67.8pp	-32.1%-6.2pp	-25.9%-223.3pp	197.4%	N/A	N/A	N/A	N/A	-247.8%-193.3pp	-54.4%+20.5pp	-75.0%+6.8pp	-81.8%	N/A	N/A
Return on Assets	21.8%+37.7pp	-15.9%-1.5pp	-14.4%-158.0pp	143.6%+196.8pp	-53.2%+6.1pp	-59.3%-1.4pp	-57.8%-19.4pp	-38.5%+26.2pp	-64.7%-34.8pp	-29.8%+30.9pp	-60.7%+9.5pp	-70.2%	N/A	N/A
Current Ratio	10.93+5.9x	5.02-0.4x	5.39-6.9x	12.31+8.0x	4.26+1.1x	3.18+0.2x	3.03-2.4x	5.41-0.6x	6.05-4.7x	10.73+5.9x	4.80-1.9x	6.67+6.3x	0.38	N/A
Debt-to-Equity	0.64-0.4x	1.02+1.0x	0.00-0.4x	0.37	N/A	N/A	N/A	N/A	1.94+1.1x	0.83+0.6x	0.23+0.1x	0.17	N/A	N/A
Asset Turnover	0.220.0x	0.180.0x	0.15+0.1x	0.08-0.1x	0.150.0x	0.150.0x	0.18+0.1x	0.11+0.1x	0.030.0x	0.08-0.1x	0.14+0.1x	0.030.0x	0.01	N/A
FCF Margin	221.9%	-18.4%+32.9pp	-51.3%	-365.3%	-382.0%	-357.7%	-328.8%	-199.0%	-1322.4%	-207.9%	-407.1%	-1525.2%	-54731.4%	-93.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Operating Margin	-39.9%-29.5pp	-53.6%+40.2pp	43.6%+92.7pp	-32.3%+32.0pp	-10.4%	-93.8%-16.5pp	-49.1%-13.5pp	-64.3%-8.4pp
Net Margin	-28.4%	-27.9%+60.4pp	133.0%	18.1%+93.4pp	209.3%	-88.2%-7.8pp	-82.8%-34.3pp	-75.3%-18.3pp
Return on Equity	-2.0%-26.4pp	-1.7%+6.5pp	20.6%+29.4pp	1.6%+8.4pp	24.4%+32.9pp	-8.2%-2.5pp	-8.8%-4.8pp	-6.8%-3.2pp
Return on Assets	-1.3%-14.1pp	-1.0%+2.9pp	12.6%+17.0pp	0.9%+4.4pp	12.9%+17.4pp	-4.0%-0.8pp	-4.4%-2.1pp	-3.6%-1.4pp
Current Ratio	13.54+6.8x	13.14+8.4x	10.93+5.9x	9.48+4.5x	6.70+1.5x	4.77-1.0x	5.02-0.4x	4.97-1.4x
Debt-to-Equity	0.62-0.3x	0.63-0.4x	0.64-0.4x	0.79-0.1x	0.890.0x	1.07+0.3x	1.02+1.0x	0.92+0.2x
Asset Turnover	0.040.0x	0.040.0x	0.090.0x	0.050.0x	0.060.0x	0.040.0x	0.050.0x	0.050.0x
FCF Margin	N/A	N/A	-13.2%-7.4pp	-32.6%-1.7pp	N/A	N/A	-5.8%+2.9pp	-30.9%-14.9pp

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Theravance Biopharma, Inc. TBPH	FY2025	$107.5M	$105.9M	98.5%	$884.2M	77/100
Day One Biopharmaceuticals, Inc. DAWN	FY2025	$158.2M	N/A	N/A	$2.2B	51/100
Relay Therapeutics, Inc. RLAY	FY2025	$15.4M	-$276.5M	N/A	$3.8B	50/100
Nurix Therapeutics, Inc. NRIX	FY2025	$84.0M	-$264.5M	N/A	$2.3B	54/100
Rezolute, Inc. RZLT	FY2026	N/A	-$77.6M	N/A	$448.8M	—
Rigel Pharmaceuticals Inc. (New) RIGL	FY2025	$294.3M	$367.0M	N/A	$910.1M	62/100

Where Theravance Biopharma, Inc. Ranks

Frequently Asked Questions

What is Theravance Biopharma, Inc.'s annual revenue?

Theravance Biopharma, Inc. (TBPH) reported $107.5M in total revenue for fiscal year 2025. This represents a 66.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Theravance Biopharma, Inc.'s revenue growing?

Theravance Biopharma, Inc. (TBPH) revenue grew by 66.9% year-over-year, from $64.4M to $107.5M in fiscal year 2025.

Is Theravance Biopharma, Inc. profitable?

Yes, Theravance Biopharma, Inc. (TBPH) reported a net income of $105.9M in fiscal year 2025, with a net profit margin of 98.5%.

What is Theravance Biopharma, Inc.'s EBITDA?

Theravance Biopharma, Inc. (TBPH) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Theravance Biopharma, Inc.'s operating margin?

Theravance Biopharma, Inc. (TBPH) had an operating margin of -3.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Theravance Biopharma, Inc.'s net profit margin?

Theravance Biopharma, Inc. (TBPH) had a net profit margin of 98.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Theravance Biopharma, Inc.'s return on equity (ROE)?

Theravance Biopharma, Inc. (TBPH) has a return on equity of 35.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Theravance Biopharma, Inc.'s free cash flow?

Theravance Biopharma, Inc. (TBPH) generated $238.5M in free cash flow during fiscal year 2025. This represents a 2109.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Theravance Biopharma, Inc.'s operating cash flow?

Theravance Biopharma, Inc. (TBPH) generated $238.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Theravance Biopharma, Inc.'s total assets?

Theravance Biopharma, Inc. (TBPH) had $485.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Theravance Biopharma, Inc.'s capital expenditures?

Theravance Biopharma, Inc. (TBPH) invested $42K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Theravance Biopharma, Inc. spend on research and development?

Theravance Biopharma, Inc. (TBPH) invested $37.4M in research and development during fiscal year 2025.

How many shares does Theravance Biopharma, Inc. have outstanding?

Theravance Biopharma, Inc. (TBPH) had 51M shares outstanding as of fiscal year 2025.

What is Theravance Biopharma, Inc.'s current ratio?

Theravance Biopharma, Inc. (TBPH) had a current ratio of 10.93 as of fiscal year 2025, which is generally considered healthy.

What is Theravance Biopharma, Inc.'s debt-to-equity ratio?

Theravance Biopharma, Inc. (TBPH) had a debt-to-equity ratio of 0.64 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Theravance Biopharma, Inc.'s return on assets (ROA)?

Theravance Biopharma, Inc. (TBPH) had a return on assets of 21.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Theravance Biopharma, Inc.'s Altman Z-Score?

Theravance Biopharma, Inc. (TBPH) has an Altman Z-Score of 1.47, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Theravance Biopharma, Inc.'s Piotroski F-Score?

Theravance Biopharma, Inc. (TBPH) has a Piotroski F-Score of 6 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Theravance Biopharma, Inc.'s earnings high quality?

Theravance Biopharma, Inc. (TBPH) has an earnings quality ratio of 2.25x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Theravance Biopharma, Inc. cover its interest payments?

Theravance Biopharma, Inc. (TBPH) reported an operating loss of $3.6M against $2.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Theravance Biopharma, Inc.?

Theravance Biopharma, Inc. (TBPH) scores 77 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.